Outlook Therapeutics, Inc. (OTLK)

Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer

Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company's Next Chapter in Virtual Investor Discussion

Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)

Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment

Reviewing Synlogic (NASDAQ:SYBX) and Oncobiologics (NASDAQ:OTLK)

Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand

Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment

Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™

Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Oncobiologics Q3 Earnings Call Highlights

Contrasting Oncobiologics (NASDAQ:OTLK) & enGene (NASDAQ:ENGN)

Outlook Therapeutics, Inc. (OTLK) Q3 2026 Earnings Call Transcript

Oncobiologics Q3 Earnings Call Highlights

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™

Outlook Therapeutics Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants

Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants

Reviewing Oncobiologics (NASDAQ:OTLK) and Pasithea Therapeutics (NASDAQ:KTTA)